Compugen
From Code
to Cure™
Therapeutic product discovery
In the information age
The next wave in immuno-oncology

NEWS

ALL NEWS

DISCOVERY

Holon

Our optimized process for predictive discovery of novel drug targets
READ MORE

DEVELOPMENT

San Francisco

Discovery & development of first-in-class monoclonal antibody therapeutics
READ MORE

Compugen, FROM CODE TO CURE

Our Pipeline

COM701/PVRIG (CGEN-15029)

CGEN-15029 is the internal designation for PVRIG, a novel B7/CD28-like immune checkpoint target candidate discovered by...
READ MORE

COM902/TIGIT (CGEN-15137)

CGEN-15137 is the internal designation for TIGIT, an immune checkpoint in the B7/CD28 family which has recently gained broad...
READ MORE

CGEN-15001T

CGEN-15001T is a novel B7/CD28-like immune checkpoint target candidate discovered by Compugen. CGEN-15001T is expressed in various subpopulations of immune cells...
READ MORE

CGEN-15001

CGEN-15001 is our lead program for autoimmune diseases. It is a first-in-class therapeutic candidate of a novel inhibitory checkpoint pathway, with the potential to restore...
READ MORE
MORE EVENTS

Collaborations

In August 2013, Compugen entered into a collaboration and license agreement with Bayer HealthCare ...
In March 2018, Compugen entered into an exclusive license agreement with MedImmune, the global biologics research and ...
Click here for more info about partnering with Compugen